Skip to content
Back to search

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sevelamer hydrochlorid, ATC V03AE02 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. V.-Option 1x12 Monate)

DAK-GesundheitGermanyPublished on Nov 16, 2026
1,084 days left

Description

Section 130a, paragraph 8, of the German Social Code (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-specific, formal tendering procedures is carried out by DAK-Gesundheit in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the above-mentioned active substance Sevelamer hydrochloride, ATC V03AE02, DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the authorisation model for the above-mentioned active substance will come into force for the first time on 01.01.2027 and will end on 31.12.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, irrespective of this.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders